Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Receivables: 2015-2025

Historic Change in Receivables for Agios Pharmaceuticals (AGIO) over the last 8 years, with Sep 2025 value amounting to $43,000.

  • Agios Pharmaceuticals' Change in Receivables rose 106.68% to $43,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 1.60%. This contributed to the annual value of $1.3 million for FY2024, which is 115.07% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Change in Receivables is $43,000, which was down 97.38% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Change in Receivables peaked at $8.1 million during Q2 2021, and registered a low of -$7.0 million during Q4 2021.
  • For the 3-year period, Agios Pharmaceuticals' Change in Receivables averaged around $256,636, with its median value being $309,000 (2024).
  • The largest annual percentage gain for Agios Pharmaceuticals' Change in Receivables in the last 5 years was 431.39% (2025), contrasted with its biggest fall of 218.97% (2025).
  • Over the past 5 years, Agios Pharmaceuticals' Change in Receivables (Quarterly) stood at -$7.0 million in 2021, then surged by 105.55% to $388,000 in 2022, then skyrocketed by 321.13% to $1.6 million in 2023, then slumped by 39.35% to $991,000 in 2024, then soared by 106.68% to $43,000 in 2025.
  • Its Change in Receivables stands at $43,000 for Q3 2025, versus $1.6 million for Q2 2025 and -$765,000 for Q1 2025.